Supplement
Saffron
A spice with a real antidepressant trial literature, graded down for how small and concentrated that literature is.
Saffron is the stigma of the crocus flower, the world's most expensive spice by weight, standardized in supplements to its crocin and safranal content. We grade Saffron B- on evidence and C+ for worth-it at about $20-35 per month.
Evidence
Worth it
Typical cost: $20-35/month
What it does
Saffron is the stigma of the crocus flower, the world's most expensive spice by weight, standardized in supplements to its crocin and safranal content. It is studied and sold mainly for mood: depression and anxiety, with side literatures in ADHD, cognition, and eye health.
What the research says
Reduces depressive symptoms versus placebo, and matched standard antidepressants in small head-to-head trials
Evidence: moderate. Meta-analyses pooling roughly a dozen small randomized trials of saffron stigma extract (usually 30 mg/day, 6 to 8 weeks) find significant symptom improvement over placebo, and individual trials report comparability with fluoxetine, imipramine, and citalopram at standard doses. The caveats are structural: nearly all trials are small, short, and from one country's research groups, with publication-bias risk. Promising and unproven-at-scale is the accurate label.
Early signals in ADHD, cognition, and PMS, all one or two trials deep
Evidence: emerging. One six-week trial found saffron comparable to methylphenidate for ADHD symptoms in children (Baziar 2019); small trials report comparability with donepezil in mild Alzheimer's disease and benefit in premenstrual symptoms. Each of these is a single small study awaiting replication, and the record treats them as leads, not findings.
Retinal function signals in early macular degeneration
Evidence: emerging. Small Italian trials (Piccardi and colleagues) report improved retinal flicker sensitivity with 20 mg/day in early AMD. Interesting, mechanistically plausible via antioxidant content, and far from an eye recommendation.
The most surprisingly substantial file among the botanicals in this tier: multiple meta-analyses, consistent direction, head-to-head comparability with real drugs in small trials. What holds it at B- is the base's shape: a dozen or so small, short trials concentrated in one research culture, with effect sizes that will almost certainly shrink when larger independent trials run. That is the same profile this library grades B- elsewhere, and saffron earns it on the same terms.
The week's longevity and biohacking news.
This grade for Saffron rests on the record above. When a new result changes that record, the grade changes with it, and the Thursday email is where the change lands first: the week's longevity and biohacking news, in plain English, linked back to the reasoning on this page.
The week's longevity and biohacking news. Every story graded against the evidence. Free. Unsubscribe anytime.
Every grade follows a published rubric, and sponsors never change one. When the evidence moves a grade, Thursday is where you hear it first, before you renew a stack that stopped earning its cost.
Is it worth it?
Evidence (B-) clears the leaderboard floor, and the worth-it grade is the derived value at this price: about $27 a month at the studied dose. Derived from the October 2026 worth-it model.
Typical cost
$20-35/month
Common form, not a brand recommendation
Dosage context established
Trials used 30 mg/day of stigma extract (15 mg twice daily is common), standardized in better products to safranal and crocin content. Whole saffron threads at culinary doses deliver far less. Adulteration is endemic in this market (dyed substitutes and diluted stigma are documented across the supply chain), so a suspiciously cheap saffron supplement is usually exactly that; standardized extracts from named suppliers are the trial-comparable form.
Worth-it leaderboard
Saffron sits outside the worth-it top 20.
Saffron sits outside the current top 20 on the gated leaderboard. The leaders below clear an evidence floor of B- before price counts at all, so cheap alone never earns a rank.
See the full worth-it leaderboard →
When the evidence moves a grade, this ranking moves with it. Thursday is where you hear it first.
Safety notes
At the studied 30 mg/day, adverse effects are mild (headache, nausea, dry mouth) and comparable to placebo in trials. Dose discipline matters with this plant: gram-level intakes are toxic, and saffron has a long history as an abortifacient at high doses, so supplemental doses are out in pregnancy. It can add to serotonergic medication effects in principle; anyone combining it with an antidepressant should treat the combination as a clinician conversation, which is also true of switching or stopping prescribed treatment, something no supplement trial justifies doing alone.
Longevity Lab Report
Saffron news. Graded when it happens.
The grade on this page stays free. The email carries the news on saffron: expert moves, dose changes, and what is working, in plain English every Thursday.
Changelog
Last updated 2026-10-23
- 2026-10-23|Graded from the depression meta-analyses and the head-to-head antidepressant trials, with the structural caveats (small, short, geographically concentrated trial base) printed in the record rather than left to the fine print of the sources.
- 2026-10-23|Listed under stress and cognition, matching this record's graded mood and early cognition findings.